News

MEPs greenlight EU patent
Enlarge image

RegulatoryEU

MEPs greenlight EU patent

14.12.2012 - After decades of deadlock, Europe is finally set to get a new unified patent. This week the Competitiveness Council and MEPs adopted the draft law.

Provided the draft law will be signed by at least 13 EU member states, EU patents must be only translated into three languages cutting the cost drastically. Today, two thirds of the patent cost of €36,000 is translation cost. The new unitary patent is calculated to cost a maximum of only €6,425, with the costs of translation set to range from €680 to €2,380. However, this is still twice as expensive as an US patent.  “Today’s vote is good news for the EU economy and especially for small and medium-sized enterprises (SMEs),” said MEP Bernhard Rapkay.

Italian MEP Raffaele Baldassarre, who had been leading negotiations on the new translation regime, described the current cost burden as “effectively a tax on innovation. We have to understand that there is a need out there to facilitate innovation in the EU."

Under the new scheme, patent applications will have to be made in either English, French or German – and will be made available in the same three languages. MEPs also voted to fully reimburse translation costs for EU-based SMEs, non-profit organisations, universities and public research organisations - something expected to benefit small high-tech firms in particular.Renewal fees, which are responsible for much of the overall cost of the current European system, will also be set at a level to help SMEs.

“Spain and Italy have so far opted out of the unitary patent package, but could join in the decision-making process at any time,” the Parliament says. “This procedure was used to break a deadlock, mainly due to language issues, that lasted over thirty yearsThe agreement is expected to be signed in February next year, and it will come into force on 1 January 2014 or when at least 13 member states including the UK, France and Germany have ratified it. Patents on plants have been excluded from the law, previously. The legislation still has to be formally adopted by the Council, but this will take place shortly.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/eu-parliament-okays-eu-patent.html

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

FinancingSwitzerlandGermanyNetherlandsFrance

26.09.2014 Biotechnology has made the news in the stock market this month, as a wave of companies announced plans to launch IPOs on European exchanges later this year.

ResearchGermany

25.09.2014 After being hit hard by the Andromeda trial data falsification scandal, German biotech Evotec is moving back into calmer waters with new MS research projects.

FinancingNetherlands

23.09.2014 Dutch Biotech VC firm Aglaia has launched a new US$65m fund targeted towards biotechnology startups working on groundbreaking technologies aimed at preventing and curing cancer.

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ADDEX3.51 CHF12.14%
  • STRATEC BIOMEDICAL41.09 EUR4.55%
  • MEDIGENE4.00 EUR2.30%

FLOP

  • CYTOS0.18 CHF-5.26%
  • MOLOGEN6.60 EUR-2.22%
  • SANTHERA86.95 CHF-1.92%

TOP

  • PAION3.22 EUR35.3%
  • CO.DON3.14 EUR28.2%
  • FORMYCON8.20 EUR16.6%

FLOP

  • CYTOS0.18 CHF-30.8%
  • EVOTEC3.10 EUR-15.8%
  • 4SC1.04 EUR-15.4%

TOP

  • SANTHERA86.95 CHF2112.5%
  • PAION3.22 EUR228.6%
  • CO.DON3.14 EUR223.7%

FLOP

  • CYTOS0.18 CHF-95.4%
  • 4SC1.04 EUR-45.0%
  • MOLOGEN6.60 EUR-44.0%

No liability assumed, Date: 30.09.2014